These drugs were costing more than $10,000 per patient per year 10 years ago, before the Global Fund started; we are now purchasing these drugs for $150 per patient per year. That's a dramatic decline in terms of cost. We are purchasing more than 90% of these drugs from generic producers, mainly in India, South Africa, and Brazil. They produce these drugs at minimal cost, basically production cost. We've seen a decline of drug costs over the years, and probably now we have more or less reached the cost required to just produce these drugs. More than 90% are bought from generic producers in emerging economies.
On May 11th, 2010. See this statement in context.